Medtronic PLC $MDT Stock Position Raised by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Medtronic PLC (NYSE:MDT) by 4.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,757,063 shares of the medical technology company’s stock after acquiring an additional 125,415 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Medtronic were worth $264,816,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of MDT. Artisan Partners Limited Partnership lifted its holdings in shares of Medtronic by 2.6% in the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after purchasing an additional 31,314 shares in the last quarter. SageView Advisory Group LLC lifted its holdings in shares of Medtronic by 164.8% in the third quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company’s stock valued at $2,305,000 after purchasing an additional 15,062 shares in the last quarter. CSM Advisors LLC lifted its holdings in shares of Medtronic by 13.2% in the third quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company’s stock valued at $27,169,000 after purchasing an additional 33,167 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares in the last quarter. Finally, Applied Finance Capital Management LLC purchased a new stake in shares of Medtronic in the third quarter valued at $1,308,000. 82.06% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.26% of the stock is currently owned by company insiders.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic won a CE mark for its VitalFlow ECMO transport technology, expanding its critical-care portfolio in markets that accept CE certification — a direct commercial upside for its acute-care product lineup. Medtronic wins CE mark for VitalFlow ECMO transport tech
• Positive Sentiment: Medtronic emphasized momentum for the Affera cardiac arrhythmia franchise and noted a Breakthrough Device designation from FDA for related tech — this can accelerate trials, regulatory review and adoption, supporting medium-term growth in electrophysiology. Medtronic (MDT) Highlights Affera Momentum and FDA Breakthrough Device Designation
• Neutral Sentiment: Some analysts are recalibrating Medtronic’s fair value modestly (example: a trim from ~$109.08 to ~$108.00) and offering mixed views — this reflects divergence on how to value guidance and the pipeline rather than a consensus sell signal. How The Medtronic (MDT) Story Is Shifting As Guidance Meets Mixed Wall Street Views
• Neutral Sentiment: Competitive dynamics in diabetes devices continue to attract attention (analyst pieces on Dexcom and CGM market growth). A stronger CGM competitor landscape is a mixed influence: it validates market expansion but may pressure Medtronic’s share in certain segments. 3 Reasons Analysts Love DexCom (MDT)
• Negative Sentiment: Short-term selling pressure and session-to-session declines have shown up in market reports — coverage noting multi-percent drops over recent sessions is contributing to negative momentum and added volatility. Medtronic (MDT) Stock Sinks As Market Gains: Here’s Why

Medtronic Price Performance

Shares of NYSE:MDT opened at $77.77 on Wednesday. Medtronic PLC has a 1 year low of $77.39 and a 1 year high of $106.33. The business has a fifty day simple moving average of $88.06 and a 200 day simple moving average of $94.68. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. The firm has a market cap of $99.85 billion, a price-to-earnings ratio of 21.66, a P/E/G ratio of 1.86 and a beta of 0.62.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The company had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same period last year, the company earned $1.38 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts predict that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.7%. The ex-dividend date was Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Analysts Set New Price Targets

Several brokerages recently issued reports on MDT. JPMorgan Chase & Co. cut their price objective on Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Jefferies Financial Group reiterated a “hold” rating and set a $95.00 price objective on shares of Medtronic in a report on Thursday, April 23rd. CICC Research began coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating for the company. Weiss Ratings lowered Medtronic from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, April 21st. Finally, William Blair upgraded Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average target price of $107.80.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).